QUANTA Appoints Dr Selwayan Saini as Chief Operating Officer
QUANTA Appoints Dr Selwayan Saini as Chief Operating Officer
Alcester, Warwickshire, UK, 12 February 2021: QUANTA Dialysis Technologies Ltd (“QUANTA” or the “Company”), a British medical technology pioneer developing innovative dialysis products and services for the global market, today announces the appointment of
Dr Selwayan Saini as Chief Operating Officer with immediate effect.
Dr Saini brings with him over 15 years of experience working in senior operational roles in large global companies and in rapidly growing start-ups. Most recently he was Senior Director of Operations at Oxford Nanopore Technologies and prior to that he held various senior positions including CEO at Medtech Inside Biometrics and Vice President and Worldwide Director at Johnson & Johnson Medical Devices & Diagnostics. While at JNJ, he made significant contributions to chronic health management in the areas of diabetes care, whic
Quanta Dialysis Technologies: QUANTA Appoints Dr Selwayan Saini as Chief Operating Officer
QUANTA Appoints Dr Selwayan Saini as Chief Operating Officer
Alcester, Warwickshire, UK, 12 February 2021: QUANTA Dialysis Technologies Ltd ( QUANTA or the Company ), a British medical technology pioneer developing innovative dialysis products and services for the global market, today announces the appointment of Dr Selwayan Saini as Chief Operating Officer with immediate effect.
Dr Saini brings with him over 15 years of experience working in senior operational roles in large global companies and in rapidly growing start-ups. Most recently he was Senior Director of Operations at Oxford Nanopore Technologies and prior to that he held various senior positions including CEO at Medtech Inside Biometrics and Vice President and Worldwide Director at Johnson & Johnson Medical Devices & Diagnostics. While at JNJ, he made significant contributions to chronic health management in the areas of dia
Johnson & Johnson Campaign tackles rising AF challenge
The cardiac awareness raising campaign is being spearheaded by Arrythmia Alliance and Biosense Webster
‘Get Smart About AFIB’ is a new public health campaign developed to address the escalating epidemic of atrial fibrillation (AF), which has doubled in prevalence over the past decade and is predicted to rise by a further 70 per cent by 2030.
The campaign aims to generate awareness, improve knowledge and encourage better detection of AF that affects more than 40,000 people in Ireland older than 50 years.
The initiative is being spearheaded by Arrythmia Alliance and Biosense Webster, part of the Johnson & Johnson Family of Companies (J&J), to tackle the challenge of AF, now recognised as a major public health condition with high comorbidity, increased mortality and soaring healthcare costs. The campaign seeks to provide educational materials to doctors, both primary care providers and cardiologists, to support their work in